ArticleSurgical endoscopy2026
Distinguishing second primary tumors from local recurrence in type 1 gastric neuroendocrine tumors: a risk-stratified management strategy.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 1 gastric neuroendocrine tumors (gNETs) exhibit high recurrence rates. However, distinguishing true local recurrence from second primary tumors (SPTs) remains challenging.
objectivesTo characterize the endoscopic features of SPTs, identify independent risk factors, and develop a risk-stratification model to guide personalized surveillance.
methodsWe retrospectively analyzed 70 patients with type 1 gNETs at Peking University Third Hospital between May 2015 and February 2025. SPTs were strictly defined as lesions detected outside the initial resection scar during follow-up, whereas local recurrence was defined as lesions within the scar. Logistic regression was used to identify independent risk factors. A nomogram was constructed, and disease-free survival (DFS) was analyzed.
resultsDuring a median follow-up of 17 months, SPTs were identified in 38 patients (54.3%), whereas local recurrence occurred in only 6 (8.6%), confirming that post-resection lesions are predominantly SPTs. Morphologically, SPTs were significantly smaller than primary tumors (0.4 cm vs. 0.5 cm, P < 0.001) and more frequently exhibited flat morphology (36.3% vs. 17.6%, P = 0.007). Lymphovascular invasion (LVI) (OR = 10.61, P = 0.035) and submucosal invasion (OR = 4.69, P = 0.006) were identified as independent predictors. A risk-stratification nomogram based on these factors showed good discriminatory power (AUC = 0.758). Based on these factors, patients were stratified into low-, medium-, and high-risk groups. The high-risk group (with LVI and submucosal invasion) demonstrated a rapid disease progression, with no patients remaining disease-free at 3 years (P = 0.015).
conclusionsSurveillance lesions in type 1 gNETs are primarily SPTs characterized by subtle, flat morphology, necessitating high-quality endoscopic observation. The proposed risk-stratification model based on LVI and invasion depth effectively identifies high-risk patients, justifying intensified monitoring for this subgroup while reducing the burden for low-risk individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.